NCT05103332
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
See it on ClinicalTrials.gov ↗658 people
42.9%
57.1%
282 womenmiddle line = equal numbers376 men
- Phase
- PHASE2
- Paid for by
- Alnylam Pharmaceuticals
- Finished
- 2024-09-13
- Health conditions
- Hypertension
- Who could join
- Anyone
- Ages
- 18 Years – 75 Years
- Average age
- mean 58.5 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- White 65.8% · Black / African American 28.4% · Asian 4.9% · Other 0.3% · Not reported 0.3% · Native Hawaiian / Pacific Islander 0.2% · More than one race 0.2%
Women left out
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“History of any cardiovascular event within 6 months prior to randomization”
- No diabetes
Women with diabetes were turned away.
“Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus, or laboratory evidence of diabetes during screening without known diagnosis of diabetes”
Study titles and rules are shown in their original English.